Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rifaximin by Alfasigma for Collagenous Colitis: Likelihood of Approval
Rifaximin is under clinical development by Alfasigma and currently in Phase III for Collagenous Colitis. According to GlobalData, Phase III...
Rifaximin by Nexpharm Korea for Irritable Bowel Syndrome: Likelihood of Approval
Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome. According to GlobalData,...
Rifaximin by Alfasigma for Sickle Cell Disease: Likelihood of Approval
Rifaximin is under clinical development by Alfasigma and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase...
Rifaximin by Alfasigma for Collagenous Colitis: Likelihood of Approval
Rifaximin is under clinical development by Alfasigma and currently in Phase III for Collagenous Colitis. According to GlobalData, Phase III...